Washington, D.C. – Senate Democratic Leader Chuck Schumer (D-NY), along with Ranking Member of the Commerce Committee, Maria Cantwell (D-WA), and Senator Ed Markey (D-MA) sent the following letter to the Chairman of the Federal Trade Commission over demanding action the handling of Americans’ highly sensitive personal data—particularly information collected through brain-computer interface (BCI) technologies.
Today, Leader Schumer, along with Ranking Member of the Commerce Committee, Maria Cantwell (D-WA) and Senator Ed Markey (D-MA), sent the following letter to the Chairman of the Federal Trade Commission, Andrew Ferguson, demanding action over the potential exploitation or sale of Americans' private thoughts or brain data, as brain-computer interface (BCI) technologies rapidly advance. This technology allows for direct communication between a consumer’s brain and external devices, such as computers or smartphones. While the technology may offer breakthrough capabilities, the neural data it collects— capable of revealing emotional states, mental health conditions, and behavioral patterns—raises urgent questions about privacy, consent, and national security.
“The risks posed by the exploitation of sensitive neural data are not hypothetical,” the Senators wrote. “The Department of Commerce has determined that Chinese companies are using biotechnology to support military end uses, including “purported brain-control weaponry.” As the market expands, companies across the spectrum—from wellness apps to advanced medical implant developers—are collecting neural signals that may be repurposed beyond their stated use. More needs to be done to address the unique risks, sensitivities, and potential misuse associated with neural data across this broader landscape.”
With these unique risks in mind, the Senators are urging the FTC to ensure that companies developing or deploying these technologies are not engaging in deceptive, exploitative, or unfair practices.
“With the market for consumer neurotechnologies growing quickly, and companies like Neuralink pushing rapidly into direct brain-to-device communication, we urge the Federal Trade Commission to act decisively,” the Senators continued.
The Senators requested a response within 30 days outlining the Commission’s current efforts and future plans to safeguard Americans’ neural data.
The letter can be seen here and below.
***
Dear Chair Ferguson:
We write to express concern over the handling of sensitive neural data generated by the rapid development and commercialization of brain-computer interface (BCI) technologies. These systems enable direct communication between an individual’s brain and external devices, such as computers or smartphones, by detecting and translating neural activity into commands. Neural data is extremely sensitive and should be accorded the strongest privacy protection.
Unlike other personal data, neural data—captured directly from the human brain—can reveal mental health conditions, emotional states, and cognitive patterns, even when anonymized. This information is not only deeply personal; it is also strategically sensitive. While BCI technologies hold significant medical promise, a 2024 review found that a vast majority of neurotech companies collect users’ brain data with few limits, vague policies, and reserve sweeping rights to share it—often without the individual’s knowledge or clear consent.[1] Americans’ neural data must not be repurposed or transferred, without fully informed, opt-in consent. If an individual uses a BCI device for medical or cognitive support, they should not later learn their brain signals trained an AI system or were sold to third parties. And, we must ensure that Americans’ neural data is never transferred to foreign adversaries.
With the market for consumer neurotechnologies growing quickly, and companies like Neuralink pushing rapidly into direct brain-to-device communication, we urge the Federal Trade Commission to act decisively. Specifically:
The risks posed by the exploitation of sensitive neural data are not hypothetical. The Department of Commerce has determined that Chinese companies are using biotechnology to support military end uses, including “purported brain-control weaponry.”[2] As the market expands, companies across the spectrum—from wellness apps to advanced medical implant developers—are collecting neural signals that may be repurposed beyond their stated use. More needs to be done to address the unique risks, sensitivities, and potential misuse associated with neural data across this broader landscape.
Accordingly, we request the Commission respond within 30 days outlining its current efforts and plans regarding BCI technologies and the protection of neural data.
Sincerely,
Charles E. Schumer
Democratic Leader
Maria Cantwell
Ranking Member
U.S. Senate Committee on Commerce,
Science, and Transportation
Edward J. Markey
United States Senator
###